Daxor (DXR) vs Sanara MedTech (SMTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Sanara MedTech (SMTI) has outperformed Daxor (DXR) over the past year, gaining 8.4% versus a loss of 18.2%. Over five years, SMTI leads with a +6.3% price change compared with -7.5% for DXR. Sanara MedTech is the larger company by market cap ($322.2 million vs $60.8 million), about 5.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DXR | SMTI |
|---|---|---|
| Share price | $10.41 | $35.07 |
| Market cap | $60.78M | $322.22M |
| 1-day change | -0.48% | +0.06% |
| YTD return | -29.42% | +50.11% |
| 1-year return | -18.22% | +8.41% |
| 5-year return | -7.47% | +6.28% |
| P/E ratio (TTM) | 9.46 | — |
| Forward P/E | — | 64.94 |
| EPS (TTM) | $1.10 | $-0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.76 | $35.34 |
| 52-week low | $8.56 | $16.05 |
| Distance from 52-week high | -29.47% | -0.76% |
| Analyst consensus | none | none |
| Avg. price target upside | +92.12% | -0.20% |
| Average volume | 17.27K | 280.40K |
| Shares outstanding | 5.84M | 9.19M |
| Employees | — | 108 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Industrial Specialties |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Sanara MedTech is about 5.3 times larger than Daxor by market value ($322.22M vs $60.78M).
- SMTI has outperformed DXR by 26.6 percentage points over the past year.
About Daxor
DXR stock →Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit.
Health Care · Medical/Dental Instruments
About Sanara MedTech
SMTI stock →Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns.
Health Care · Industrial Specialties · 108 employees
DXR vs SMTI FAQ
Which is bigger, Daxor or Sanara MedTech?
Sanara MedTech (SMTI) is larger, with a market capitalization of $322.22M compared with $60.78M for Daxor (DXR).
Which stock has performed better over the past year, DXR or SMTI?
SMTI returned +8.41% over the past 12 months, compared with -18.22% for DXR (price return, excluding dividends). Past performance does not predict future results.
Are Daxor and Sanara MedTech in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Daxor and Industrial Specialties for Sanara MedTech.